Dalian BIO-CHEM Company Limited
603360.SS · SHH
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -3.00 | -3.98 | -1.22 | -4.18 |
| FCF Yield | 1.11% | 0.45% | -0.72% | -1.24% |
| EV / EBITDA | 379.22 | 162.14 | 122.32 | 57.06 |
| Quality | ||||
| ROIC | 1.14% | 1.44% | 1.68% | 3.55% |
| Gross Margin | 34.67% | 34.94% | 31.49% | 38.55% |
| Cash Conversion Ratio | 6.07 | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 10.07% | 8.11% | 5.22% | 1.44% |
| Free Cash Flow Growth | 275.26% | 164.58% | 20.66% | -166.01% |
| Safety | ||||
| Net Debt / EBITDA | 10.11 | 4.85 | 1.71 | -0.98 |
| Interest Coverage | 5.48 | 6.86 | 10.41 | 62.51 |
| Efficiency | ||||
| Inventory Turnover | 0.17 | 0.17 | 0.33 | 0.28 |
| Cash Conversion Cycle | 597.52 | 618.44 | 331.29 | 395.50 |